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Mark Schiffman and Mona Saraiya1 present an exciting vision of the longterm implications of data from Eric 
Chow and colleagues2 showing that female human papillomavirus (HPV) vaccination reduces transmission to 
males, bringing forward control of HPVassociated cancers “decades faster” than previously anticipated. Although 
their argument is convincing, the natural history of HPV carcinogenesis3 means that, even if there is a rapid 
reduction in HPV transmission rates, we can still expect many decades of HPV-associated cancers. Indeed, it is 
probable that a number of men in Chow and colleague’s cohort2 who tested negative for HPV had already entered 
the latent phase: transmission peaks in young adults,3 and the same mechanisms underpinning persistence also 
reduce virion assembly and release. Hence, the incidence of HPV-associated oropharyngeal cancer is still rising 
rapidly, and will overtake cervical cancer incidence in the next decade in the USA.4 
The article rightly emphasises the benefits of herd protection achieved by vaccinating girls. These benefits will 
continue to accrue over many years and are dependent on continued high female vaccination coverage. Although 
some countries have extended HPV vaccination programmes to boys, making the case on economic grounds is 
very challenging where female coverage rates are high. Meanwhile, there is likely to be benefit in ensuring that 
both men and women are aware of HPV, how it is transmitted, and the potential longterm sequelae: education 
has been shown to effectively modify sexual behaviour.4  
We did a brief survey of awareness of HPV, transmission, as well as indicator symptoms of oropharyngeal cancer 
among a similar patient group to Chow and colleague’s cohort, attending the Mortimer Market Centre, a sexual 
health clinic in London, UK (figure). 466 questionnaires were completed; 295 (63%) respondents were men. 249 
participants (53%) had heard of HPV. 175 (61%) of 287 thought that HPV can be transmitted during oral sex, but 
only 94 (33%) of 289 were aware that HPV is a risk factor for oropharyngeal cancer, while 312 (67%) were unable 
to name any symptoms. No significant difference was noted in responses between men 
and women. Early data for the effect of current vaccination programmes is very encouraging but, for now, HPV-
associated cancer burden is still rising.5 As the pattern of HPV-related disease changes, there is a need to  
increase awareness—eg, of oropharyngeal cancers, a disease for which there is no screening programme. Public 
health initiatives should be explored that could improve awareness and lead to earlier diagnosis and improved 
outcomes. 
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